Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma
Status:
Unknown status
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
Initially, the prospect of metformin as a neoplastic treatment was considered for
malignancies of the prostate, colon and pancreas. However, only select clinical studies
involving the use of metformin in the treatment of ovarian cancer have documented improved
survival rates. Since no first line regimen has demonstrated compelling superiority in the
management of advanced stage ovarian carcinoma, the combination of paclitaxel, carboplatin,
and metformin is of particular interest given the triplet's prospect for achieving increased
synergy without compromising patient tolerability.